Table 2.
Management and follow-up of patients with tuberculosis.
| 2019 Cohort | 2020 Cohort | P value | |
|---|---|---|---|
| N = 90 | N = 79 | ||
| More than one consultation previous to diagnosis | 44 (48.9%) | 39 (49.4%) | 0.982 |
| Tested for SARS-CoV-2 | |||
| Home isolation due to SARS-CoV-2 suspicion | – | 59 (74.7%) | – |
| Need for hospital admission during diagnosis | – | 19 (24.1%) | – |
| Need for hospital admission during Follow-upa | |||
| Initial treatment regimen | 53 (59.6%) | 52 (66.7%) | 0.422 |
| Rifampin based treatment | |||
| Rifabutin based treatment | 12 (13.3%) | 11 (13.9%) | 0.412 |
| Quinolones supplemented treatment | |||
| AFB conversion time (days), median (IQR) | |||
| Treatment adherence (≥75%) | 88 (97.7%) | 73 (92.4%) | 0.488 |
| Adverse effects | 0 | 1 (1.2%) | |
| Treatment interruption | 2 (2.2%) | 4 (5.1%) | |
| 33·5 (21.7–45.7) | 34 (14–45) | 0.306 | |
| 83 (92.2%) | 75 (94.9%) | 0.509 | |
| 24 (26.7%) | 13 (16.5%) | 0·212 | |
| 9 (10.0%) | 5 (6.3%) | 0.083 | |
| Number (median, SD) of FU visitsb | 2 (1–3) | 1 (1–2) | 0.002 |
| Type of FU visits | |||
| Face-to-face visit | 58/71 (81.7%) | 40/59 (67.8%) | 0.006 |
| Telephone | 0 | 11/59 (18.6%) | |
| Both (face-to-face and telephone) | 9/71 (12.7%) | 4/59 (6.8%) |
RMP = rifampin; INH = isoniazid; PZA = pyrazinamide; ETB = ethambutol; Rb = rifabutin; Mx = moxifloxacin; Lx = levofloxacin; AK = amikacin.
a
Patients who were admitted for diagnosis but could not be discharged during the first month of follow-up were also included.
b
Patients who needed hospital admission during diagnosis were excluded.